Irene Tsung

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (10)

• Prospective Evaluation of Circulating Tumor DNA in Metastatic Hormone-Sensitive Prostate Cancer
  JCO Precision Oncology 2026 DOI: 10.1200/PO-25-01218
  +Save
• Phase II trial of Pembrolizumab and Lenvatinib in Advanced Neuroendocrine Prostate Cancer (PLANE-PC)
  2026 DOI: 10.21203/rs.3.rs-9471666/v1
  +Save
• Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the UNITE Database
  Clinical Genitourinary Cancer 2026 DOI: 10.1016/j.clgc.2026.102501
  +Save
• Pathogenic Germline Variant Prevalence and Genetic Testing Outcomes in Patients With Urothelial Carcinoma
  Clinical Genitourinary Cancer 2025 DOI: 10.1016/j.clgc.2025.102451
  +Save
• Reply to “From treatment escalation to ultra de‐intensification: When androgen‐deprivation therapy alone remains a rational choice in metastatic hormone‐sensitive prostate cancer”
  Irene Tsung, Zachery Roger Reichert
  Cancer 2025 DOI: 10.1002/cncr.70119
  +Save
• Multicenter Phase II Study of Olaparib and the ATR Inhibitor Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (TRAP)
  JCO Precision Oncology 2025 DOI: 10.1200/PO-25-00457
  +Save
• Controversies in metastatic hormone‐sensitive prostate cancer
  Cancer 2025 DOI: 10.1002/cncr.70030
  +Save
• A Phase 2 Trial of Nab-paclitaxel in Combination With Anti-PD1 Therapy in Advanced Urothelial Cancer
  Journal of Urology 2023 DOI: 10.1097/JU.0000000000002969
  +Save
• Infrequent Liver Injury from Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma
  Immunotherapy 2022 DOI: 10.2217/imt-2021-0191
  +Save
• A Pilot Study of Checkpoint Inhibitors in Solid Organ Transplant Recipients with Metastatic Cutaneous Squamous Cell Carcinoma
  The Oncologist 2021 DOI: 10.1002/onco.13539
  +Save